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Abstract: Pain is a frequent and important symptom in cancer patients. Among the available 
strong opioids, transdermal buprenorphine has been licensed in Europe since 2002, and results 
from a few clinical studies suggest that it may be a good alternative to the other oral or transdermal 
opioids. To assess the best available evidence on its efficacy and safety, we carried out a system-
atic literature review with the aim of pooling relevant studies. We identified 19 eligible papers 
describing 12 clinical studies (6 randomized controlled trials and 6 observational prospective 
studies), including a total of about 5000 cancer patients. Given the poor quality of reports and 
the heterogeneity of methods and outcomes, pooling was not feasible as the type of data was 
not appropriate for combining the results statistically. A meta-analysis based on individual data 
is ongoing in the context of the Cochrane Collaboration. In conclusion, although the narrative 
appraisal of each study suggests a positive risk benefit profile, well designed and statistically 
powered controlled clinical trials are needed to confirm this preliminary evidence.
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Introduction
Advances in prevention, diagnosis, and therapy have extended the life expectancy of 
cancer patients, but improvement in the survival is still disappointing for most com-
mon tumors, mostly when the disease is diagnosed at advanced or metastatic stages. 
Despite the availability of new and innovative anti-cancer drugs, metastatic patients 
are indeed unlikely to have important benefit from these treatments either in terms of 
quantity and quality of life. For most of these patients, the later part of their lives is 
impaired by pain, fatigue, depression, and other symptoms related to the disease and 
treatments, which become prominent contributors to suffering. Pain, in particular, is 
one of the most important problems. Most patients with advanced or metastatic cancer 
experience pain during their life1,2 and despite effective treatments being available, 
undertreatment has been documented in nearly one of two patients with cancer pain, 
with a few differences according to geographical, economic, and cultural factors.3 The 
use of analgesic pharmacotherapy is the mainstay of all guidelines on pain management 
which are available since 1986.4–7 The World Health Organization (WHO) suggested 
that the choice of analgesics should be based on pain intensity, and not simply on its 
etiology; the preferred route of administration should be oral, for drugs ranging from 
paracetamol and NSAID to strong opioids, morphine being the first choice.4 Since then, 
a broad spectrum of analgesics has become available, such as morphine, methadone, 
hydromorphone, oxycodone, fentanyl, and buprenorphine, which have been shown Therapeutics and Clinical Risk Management 2009:5 708
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to be effective in treating moderate to severe cancer-related 
pain. In addition to the traditional analgesics that are deliv-
erable orally or parenterally, a few transdermal delivery 
systems (TDS) containing fentanyl or buprenorphine have 
been introduced onto the market, suggesting a potential for 
improvement in view of their advantages over the oral and 
parental routes, in terms of non-invasiveness and slow and 
continuous release of the compound. A recent review has 
pointed out the advantages and disadvantages of available 
TDS for cancer pain, focusing on the problem of transdermal 
dosing conversion.8 Another very recent review updated the 
pharmacological properties of transdermal buprenorphine 
with a focus on its ceiling effect,9 and also qualitatively 
summarized the clinical efficacy and tolerability of TDS 
containing buprenorphine, using results from clinical studies 
including cancer patients, as primary evidence. As this work 
combined the early and late randomized placebo and com-
parative trials with retrospective and prospective studies, 
it was difficult to obtain an overall quantitative estimate 
of the yield of TDS containing buprenorphine in terms of 
efficacy and safety.
Our paper is based on a systematic review of published 
literature with the aim of assessing the best available 
evidence for the effect of TDS containing buprenorphine in 
chronic cancer pain. We have searched, identified, appraised, 
selected, and integrated all relevant publications on this topic 
and attempted to combine statistically the valid studies. The 
results and comments are presented according to the study 
design (randomized clinical trials vs observational studies) 
and are based on 19 papers reporting data from 12 prospective 
studies involving more than 5000 patients.
Materials and Methods
Synthetic profile of buprenorphine
Excellent profiles of the pre-clinical and clinical pharmacology 
of buprenorphine have been reported elsewhere.9–11
Briefly, buprenorphine is a semi-synthetic compound 
derived from tebaine, a natural opium alkaloid, which is 
structurally similar to morphine, even if several molecu-
lar differences confer a higher lipophilicity and a higher 
pharmacological potency.
Pharmacokinetically, buprenorphine shows very low 
bioavailability (about 15%) after oral administration,12,13 
because of an intense metabolic degradation at the intestinal 
and hepatic level (first pass). After transdermal administra-
tion, the plasma concentration remains more or less steady 
as a consequence of continuous delivery of the drug. A very 
high percentage of available buprenorphine is strongly bound 
to plasma proteins,14 and only the unbound fraction that 
consists of 3% to 5% of the total plasma buprenorphine may 
cross the blood–brain barrier. Transit across the blood–brain 
barrier is regulated by several factors, the most impor-
tant being the free fraction of the drug, and lipophilicity. 
Among the opioids, buprenorphine has an intermediate to 
high lipophilic property. Once buprenorphine has crossed 
the blood–brain barrier, it must reach its biological target, 
the opioids receptors (ORs). Buprenorphine presents a high 
selectivity for the MOR (µ-ORs). In an in vitro study,15 the 
Ki values of buprenorphine were 0.08 for the MOR, 0.11 
for the KOR, and 0.42 for the DOR. For pharmacological 
efficacy, buprenorphine presents 60% to 65% with respect 
to MOR (partial agonist).16–22 These results confirm that the 
analgesic activity of buprenorphine is mainly mediated by 
MOR; its partial agonist action reflects the potential exis-
tence of a ceiling effect that, in clinical practice, has been 
estimated to be about 15 to 25 mg daily,23 a dosage that 
may not be compatible with the doses usually prescribed in 
clinical practice.
In terms of pharmacokinetics, two different metabolic 
pathways have been observed to work in parallel: the first 
consists of N-dealkylization by means of CYP3A4, and the 
second produces three glycuronized compounds. The first 
metabolic pathway generates nor-buprenorphine, the only 
molecule having some biological activity. Buprenorphine 
is eliminated through two routes: unchanged molecules are 
excreted mainly via the biliary system, whereas metabolites 
are eliminated via renal excretion, but metabolite accu-
mulation is of minimal importance given that these agents 
are substantially inactive substances.24 For these reasons 
buprenorphine may be considered as a safe opioid in cases of 
reduced renal function, which is a frequent clinical condition 
in cancer patients, especially in the far advanced phase.9
Transdermal buprenorphine  
in pain management
Buprenorphine was first synthesized in the late 1960, and 
introduced in clinical practice for parenteral and sublingual 
(SL) administration in 1978 and 1981, respectively. In the 
late 1990s, it was introduced as a transdermal formulation, 
contained in a matrix patch that can be applied to the skin for 
a duration of up to 4 days, which was indicated for moderate 
to severe cancer and chronic pain unrelated to cancer. The 
continuous release from the matrix across the skin and then 
into the systemic circulation is regulated mainly by the concen-
tration gradient across the skin and the patch.25 In the matrix 
patch, the drug is an integral part of the polymer structure, Therapeutics and Clinical Risk Management 2009:5 709
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making the delivery system more robust than the reservoir 
patch. This feature prevents “dose-dumping” and potential 
overdosing either intentionally or unintentionally, as damag-
ing the patch does not interfere with the controlled release of 
medication. TDS containing buprenorphine is available with 
release rates of 35, 52.5, and 70 µg/hour (Transtec®) that cor-
respond to 0.8, 1.2, and 1.6 mg/day of buprenorphine or 60, 90, 
and 120 mg/day equivalent of oral morphine, respectively.25,26 
Recently, low-dose patches (5 to 20 µg/hour released for 
7 days) have been marketed in a few countries.26
Transtec® has been available since 2002 in 18 European 
countries including Russia and three South American 
countries.
Search strategy and study selection
MEDLINE (from 1966 to April 2009), EMBASE, and the 
Cochrane Library were searched, and only papers written in 
English were taken into account for data extraction; the main 
search terms were: ‘pain’, ‘neoplasms’, ‘buprenorphine’, 
‘transdermal’, and ‘randomized controlled trial’ (RCT), 
as well as combinations of these terms. The complete search 
strategy can be obtained from the authors on request. Refer-
ences in the published articles, reviews, meta-analyses, and 
relevant organization websites were checked. No systematic 
attempt was made to identify unpublished studies.
Data extraction and synthesis
The eligibility assessment of the titles and abstracts was 
performed in a standardized manner by one reviewer (SD). 
Two reviewers (SD and GA) independently screened the 
full papers. Disagreements were resolved by discussion 
and consensus. Details of the study design, participants, 
inclusion criteria, clinical setting, study duration, definition 
of outcomes and endpoints, and results were recorded and 
summarized. Given the heterogeneity of the studies and the 
difficulty of extracting quantitative disaggregated informa-
tion from each study, we undertook a narrative synthesis of 
each study. Eligible studies were then grouped based on the 
study design (randomized vs observational). Data from the 
studies reporting the use of standardized measures of pain 
intensity were grouped, described, and integrated. In this 
case, an attempt to summarize the results of the studies report-
ing the use of standardized measures of pain intensity has 
been attempted using appropriate statistical methods.27
Results
The search of MEDLINE and EMBASE with the review of 
titles and abstracts, integrated by scanning the references and 
consulting experts in the field, yielded 27 relevant articles. 
Four articles were excluded because they were published 
as abstracts and/or full text was not available, and the other 
four were excluded because they were written in languages 
other than English. Figure 1 presents a flowchart of manu-
script selection.
The main characteristics of the remaining 19 papers28–46 
are reported in Table 1. The 19 published articles described 
16 different studies: Radbruch29 presented the aggregated data 
from Bohme,28 Sittl,31 and Sorge;32 Evans reported efficacy 
and safety data by pooling the 3 placebo-controlled RCTs;25 
and Radbruch30 and Apolone35 reported the preliminary 
information later published by Griessinger33 and Apolone,46 
respectively. Nine were clinical trials28,31,32,37,39–42,44 and 7 were 
observational (non-intervention) studies.33,34,36,38,43,45,46
Most of the papers reported data from a mixed popula-
tion including both cancer and non-cancer patients (12/19).
Three experimental studies were subsequently excluded 
because they were early-phase feasibility trials: a rotation 
feasibility trial describing cross-over administration of two 
drugs,41 a pilot study describing the effect of pre-planned rota-
tion administration of several drugs,39 and a dose escalation 
administration trial.37 The characteristics of the remaining 
6 studies,28,31,32,40,42,44 involving 499 cancer patients (range 
9 to 189) are reported in Table 2A.
One observational study was also excluded, because it 
was focused on assessing the effect of buprenorphine TDS 
across pre-planned age groups, to test its effectiveness in 
a special population:43 the characteristics of the remaining 
6 studies (4599 cancer patients, range 6 to 3690) are reported 
in Table 2B.
RCTs
Six RCTs were available for analysis and discussion. Details 
of the papers and the studies are summarized in Tables 2A 
and 3. Studies may be classified into 3 types: 3 preliminary 
pivotal studies comparing TDS buprenorphine vs placebo, 
2 testing different schedules and a maintenance regimen, 
respectively, and 1 comparative trial vs morphine.
The first Phase III studies were 3 multicenter, randomized, 
double-blind clinical trials vs placebo (Bohme,28 Sittl,31 
Sorge)32 in patients with chronic cancer and non-cancer pain, 
initiated and sponsored by the industry marketing in Europe 
the drug under evaluation. In the first and the third study, 
only patients whose pain was satisfactorily relieved after 
a run-in phase with buprenorphine SL were randomized. 
In the study by Sorge,32 only 35 µg/hour dose strength was 
allowed; the 3 dose strengths (35, 52.5, and 70 µg/hour) Therapeutics and Clinical Risk Management 2009:5 710
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were used by Bohme28 and Sittl.31 In the first 2 studies, 
the primary outcome was the responder’s status defined as 
‘patients whose pain relief was at least satisfactory at all 
determination points (excluding the final examination) and 
who took a mean of 0.2 mg/day or less of SL buprenorphine 
on days 7–12’ (Bohme)28 and ‘any patient who required no 
more than 1 SL tablet of buprenorphine as rescue medication 
per day from day 2 until the end of the study and who 
recorded at least satisfactory pain relief at each application 
of a new patch’ (Sittl).31 The third study, on the contrary, 
used only the rescue therapy as the primary outcome, in 
terms of the number of buprenorphine SL tablets required 
each day. Bohme28 reported a percentage of responder 
patients of 34% for 35 µg/hour, 37% with for 52.5 µg/hour, 
and 50% for 70 µg/hour, but these response rates failed to 
reach statistical significance. The proportion of patients 
reporting good to complete pain relief, none to mild pain on 
a verbal rating scale (VRS), and an uninterrupted sleep for 
more than 6 hours increased during the double-blind phase, 
but the authors do not report a test of statistical significance 
vs placebo. Overall, 23% of the patients reported adverse 
events, with no statistically significant differences between 
the treatment groups. In the study by Sittl,31 the percentage 
of responders was very similar to that in the Bohme28 study 
(ie, 36.6%, 47.5%, and 33.3% for the 3 dosages); also, in 
this case, the difference vs placebo failed to reach statistical 
significance in the 70 µg/hour patch. Buprenorphine seemed 
to give better results than the placebo also in terms of rescue 
therapy (P = 0.002), pain relief, pain intensity, and duration 
of sleep uninterrupted by pain (P value not reported). The 
percentage of patients reporting at least 1 adverse event was 
high for both buprenorphine (85.4%, 80.5%, 75.7% for the 
3 patches) and placebo group (73.7%) with no statistical 
difference. In the study by Sorge,32 the mean daily require-
ment of buprenorphine SL tablets during the double-blind 
phase was lower than that required during the run-in for the 
buprenorphine TDS group (−55.4%, dose-dependent) than 
for placebo (−45.1%, P = 0.01), but was similar in terms of 
mean number of daily dose (in mg) consumed (0.5 for all 
patients, 0.4 vs 0.6 for cancer patients). Pain intensity, pain 
relief, and sleep quality evaluation suggested a better effect 
of buprenorphine, although a statistical significance was not 
reached or it was not evaluated or reported. Adverse events 
were reported in 54.4% of the buprenorphine TDS group and 
42.6% of the placebo group with no significant difference. 
Radbruch29 reported the aggregated results of these 3 RCTs 
and classified the patients according to the disease: among 
the cancer patients, 36% of those with 35 µg/hour patch and 
42% and 40% of those with the 52.5 and 70 µg/hour patch 
were classified as responders vs 23% of the placebo.
Likar40 compared the efficacy and tolerability of the 2 
different delivery schedules in subjects who have already 
responded to buprenorphine: patients (only 9 with cancer) 
were randomized to a treatment sequence in which they 
changed the buprenorphine patch every 3 days during the 
first step of the study (3-day regimen) or every 4 days (4-day 
regimen). In the second phase, the patients crossed over to 
the alternative regimen. The 2 regimens failed to show any 
statistical difference in terms of patient’s and physician’s 
satisfaction, pain intensity assessed with a numerical rating 
scale (NRS) (3.73 for 3-day regimen and 3.88 for 4-day 
regimen), pain relief, and tolerability. The latter findings were 
presented only in an aggregated way, making it impossible to 
evaluate the effect of the 2 interventions in cancer patients.
To date, the study by Pace42 is the only comparative 
trial available. It compared the effects of buprenorphine 
of 35 µg/hour with the oral SR morphine of 60 mg/day in 
an open-label study. The patients treated with transdermal 
buprenorphine experienced significantly greater improve-
ment in pain intensity (−2.5 for buprenorphine, −1.4 for 
morphine), quality of sleep, and quality of life. Adverse 
drug reactions (ADRs) were not reported and the side effects 
that were significantly more frequent for morphine than for 
buprenorphine, were vertigo, constipation, and nausea.
Finally, more recently, another RCT vs placebo was 
conducted to evaluate the maintenance of efficacy (Poulain)44 
Citations identified by 
Medline and Embase search, 
references and experts n = 27 
Excluded because only 
abstract or poster n = 4 
Full text available n = 23
Papers on buprenorphine 
effects in adult cancer 
patients with a prospective 
study design and written in 
English n = 19 
Excluded because not 
written in English n = 4 
Figure 1 Flowchart of manuscript selection.Therapeutics and Clinical Risk Management 2009:5 711
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in severe cancer pain. Opioid-tolerant patients were 
converted to buprenorphine TDS during a run-in phase and 
then randomized for the 2-week maintenance phase; of the 
289 patients initially recruited, only 189 entered the second 
phase, because 100 discontinued the treatment for adverse 
events or lack of efficacy. The primary efficacy outcome was 
the proportion of the responder patients (defined as patients 
completing at least 12 days of the double-blind period, with 
an average pain intensity score of 5 on the numerical rat-
ing scale during the last 6 days of treatment, and not using 
Table 1 List and characteristics of the 19 papers selected
Reference Year of 
publication
Country Study design Total number 
of patients  
(cancer:non-cancer)
Remarks
Böhme28 2003 Austria, Germany 
and Hungary
Parallel double-blind  
RCT vs placebo
151  
(83:68)
Radbruch29 2003 Germany 3 parallel double-blind  
RCTs vs placebo
445  
(249:196)
Collects information from other 
studies32,35,36
Radbruch30 2003 Germany Observational 3255  
(846:2409)
Preliminary data from another 
study37
Sittl31 2003 Austria, Germany 
and The Netherlands
Parallel double-blind  
RCT vs placebo
157  
(121:36)
Sorge32 2004 Germany and Poland Parallel double-blind  
RCT vs placebo
137  
(45:92)
Griessinger33 2005 Germany Observational 13179 Post-marketing surveillance
(3690:9489)
Muriel34 2005 Spain Observational 1212 Open-label
(207:1005)
Apolone35 2006 italy Observational not reported Preliminary data from another 
study50
Likar36 2006 Austria, Germany, 
Hungary, Poland 
and The Netherlands
Observational 239  
(134:105)
Long-term follow-up of patients 
recruited in previous RCTs32,35,36
Mercadante37 2006 italy Dose escalation feasibility 
trial
10 Describes the efficacy and 
tolerability of a dosage increase 
up to 140 µg/hour
Camba38 2007 Spain Observational 762
(164:598)
Freye39 2007 Germany Rotation feasibility trial 42  
(9:33)
Describes the switch from 
high-dose morphine to TDS 
buprenorphine
Likar40 2007 Austria Crossover open-label  
RCT comparing 2 schemes
49  
(9:40)
Compares the efficacy and 
tolerability of 3-day vs 4-day 
patch change schedule
Mercadante41 2007 italy Crossover non-randomized 
clinical trial (vs fentanyl)
22 Describes the switch from one 
opioid to the other and then back 
to the previous one
Pace42 2007 italy Parallel open-label  
RCT vs morphine
52
Likar43 2008 Austria Observational 82  
(6:76)
Compares efficacy and tolerability 
in different age groups
Poulain44 2008 Austria, Belgium, 
Croatia, France, Poland, 
The Netherlands
Parallel double-blind  
RCT vs placebo
189
wirz45 2008 Germany Observational 174 Random selection of patients
Apolone46 2009 italy Observational 257 Outcome research study
Abbreviations: RCT, randomized controlled trial;   TDS, transdermal delivery system.Therapeutics and Clinical Risk Management 2009:5 712
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more than 2 tablets of rescue medication per day). More 
patients receiving transdermal buprenorphine of 70 µg/hour 
responded (74.5%) compared with those receiving placebo 
(50%) (P = 0.0003). Pain intensity was significantly lower 
in the TDS containing buprenorphine group (1.8) compared 
with placebo (2.7). In addition, the daily consumption of SL 
tablets remained stable during the double-blind phase for 
buprenorphine, but increased from 0.6 to 1.7 tablets for the 
placebo group. The incidence of adverse events was slightly 
higher for buprenorphine than for the placebo group, and the 
most commonly reported symptoms were nausea, vomiting, 
and constipation (P value not reported).
Observational prospective studies
The first observation prospective study was a post-marketing 
surveillance in Germany in 13,179 cancer and non-cancer 
patients with unsatisfactory pain relief or unacceptable side 
effects with previous therapy.33 Patients with cancer-related 
pain were about 30% of the total sample. Seventy percent of 
them started with 35 µg/hour patch, 22% with 52.5 µg/hour, 
and 7% with 70 µg/hour; patch strength was changed at visit 1 
(median 14 days) in 16% of the patients and at visit 2 (median 
40 days) in 2% of the subjects. ‘Good’ or ‘very good’ pain 
relief was obtained in 84% of the cancer patients. Twenty-
seven percent of the cancer patients experienced 1 adverse 
event (21.6% experienced serious adverse events).
Muriel34 in Spain followed up for 3 months the cancer 
and non-cancer patients who were beginning buprenorphine 
for moderate to severe pain who had not responded to non-
opioid analgesics. Patients began buprenorphine TDS at the 
lowest possible dosage, and the daily median amount at the 
baseline was 35 µg/hour (all the patients). At the end of the 
study, 22% of all the patients had been changed to a higher 
dosage. The study included 207 patients with cancer (17%). 
Sixty-five percent of these reported ‘good’ or ‘very good’ 
pain relief after 1 month, and 57% after 3 months. Other 
outcomes and adverse events were not reported for the can-
cer population alone: 63% of all the patients reported and 
improvement in the quality of sleep after 1 month, and 56% 
after 3 months, and the quality of life also improved, from a 
mean EQ-5D score of 40.6 at baseline to 56.8 at the end of 
the study (P  0.001); 42% of the patients experienced at 
least 1 adverse event during the follow-up.
Some patients recruited in the 3 registered clinical trials 
mentioned earlier,28,31,32 were subsequently included in a 
follow-up study (Likar)36 where they continued the treat-
ment with 35 µg/hour patch and SL tablets (0.2 mg). There 
were 134 cancer patients who were followed up for a mean 
T
a
b
l
e
 
2
B
 
C
h
a
r
a
c
t
e
r
i
s
t
i
c
s
 
o
f
 
6
 
o
b
s
e
r
v
a
t
i
o
n
a
l
 
p
r
o
s
p
e
c
t
i
v
e
 
s
t
u
d
i
e
s
 
i
n
v
e
s
t
i
g
a
t
i
n
g
 
b
u
p
r
e
n
o
r
p
h
i
n
e
 
T
D
S
 
e
f
f
e
c
t
s
 
i
n
 
a
d
u
l
t
 
c
a
n
c
e
r
 
p
a
t
i
e
n
t
s
N
a
m
e
 
o
f
 
t
h
e
 
fi
r
s
t
 
a
u
t
h
o
r
N
u
m
b
e
r
 
o
f
 
p
a
t
i
e
n
t
s
 
w
i
t
h
 
c
a
n
c
e
r
I
n
c
l
u
s
i
o
n
 
c
r
i
t
e
r
i
a
F
o
l
l
o
w
-
u
p
 
a
s
s
e
s
s
m
e
n
t
P
r
i
m
a
r
y
 
o
u
t
c
o
m
e
 
a
n
d
 
e
n
d
p
o
i
n
t
S
e
c
o
n
d
a
r
y
 
e
n
d
p
o
i
n
t
s
 
 
P
I
P
R
A
E
P
S
S
Q
R
T
Q
o
L
G
r
i
e
s
s
i
n
g
e
r
3
3
3
6
9
0
U
n
s
a
t
i
s
f
a
c
t
o
r
y
 
p
a
i
n
 
r
e
l
i
e
f
,
 
m
o
d
e
r
a
t
e
 
t
o
 
s
e
v
e
r
e
 
p
a
i
n
 
o
r
 
u
n
a
c
c
e
p
t
a
b
l
e
 
s
i
d
e
 
e
f
f
e
c
t
s
1
0
 
w
e
e
k
s
P
a
i
n
 
r
e
l
i
e
f
–
–
–
–
–
–
–
M
u
r
i
e
l
3
4
2
0
7
N
o
t
 
r
e
s
p
o
n
d
e
r
 
t
o
 
p
r
e
v
i
o
u
s
 
t
h
e
r
a
p
y
 
a
n
d
 
m
o
d
e
r
a
t
e
-
t
o
-
s
e
v
e
r
e
 
p
a
i
n
3
 
m
o
n
t
h
s
P
a
i
n
 
r
e
l
i
e
f
 
a
n
d
 
t
o
l
e
r
a
b
i
l
i
t
y
 
(
c
o
m
p
o
s
i
t
e
 
e
n
d
p
o
i
n
t
)
–
–
x
–
x
–
x
L
i
k
a
r
3
6
1
3
4
M
o
d
e
r
a
t
e
-
s
e
v
e
r
e
 
p
a
i
n
 
a
n
d
 
p
a
r
t
i
c
i
p
a
t
i
n
g
 
t
o
 
t
h
e
 
t
h
r
e
e
 
p
r
e
v
i
o
u
s
 
t
r
i
a
l
s
6
 
m
o
n
t
h
s
P
a
i
n
 
r
e
l
i
e
f
 
(
v
R
S
)
–
–
x
–
–
x
–
C
a
m
b
a
3
8
1
6
4
N
o
t
 
r
e
s
p
o
n
d
e
r
 
t
o
 
p
r
e
v
i
o
u
s
 
t
h
e
r
a
p
y
 
a
n
d
 
l
o
c
a
l
 
o
r
 
m
e
t
a
s
t
a
t
i
c
 
c
a
n
c
e
r
8
 
w
e
e
k
s
P
a
i
n
 
i
n
t
e
n
s
i
t
y
 
(
v
A
S
)
–
–
x
–
–
x
x
w
i
r
z
4
5
1
7
4
A
l
r
e
a
d
y
 
i
n
 
t
h
e
r
a
p
y
 
w
i
t
h
 
t
h
a
t
 
o
p
i
o
i
d
 
f
o
r
 
l
o
n
g
e
r
 
t
h
a
n
 
4
 
w
e
e
k
s
5
 
d
a
y
s
S
a
f
e
t
y
–
–
x
–
–
–
–
A
p
o
l
o
n
e
4
6
2
5
7
P
e
r
s
i
s
t
e
n
t
 
p
a
i
n
 
o
f
 
a
n
y
 
d
e
g
r
e
e
 
a
n
d
 
l
i
f
e
 
e
x
p
e
c
t
a
n
c
y
 

1
 
m
o
n
t
h
2
8
 
d
a
y
s
P
a
i
n
 
i
n
t
e
n
s
i
t
y
 
(
w
o
r
s
t
 
a
n
d
 
a
v
e
r
a
g
e
 
p
a
i
n
 
o
n
 
a
 
N
R
S
)
–
x
x
x
–
–
x
A
b
b
r
e
v
i
a
t
i
o
n
s
:
 
A
e
,
 
a
d
v
e
r
s
e
 
e
v
e
n
t
s
;
 
P
i
,
 
p
a
i
n
 
i
n
t
e
n
s
i
t
y
;
 
P
R
,
 
p
a
i
n
 
r
e
l
i
e
f
;
 
P
S
,
 
p
a
t
i
e
n
t
 
s
a
t
i
s
f
a
c
t
i
o
n
;
 
Q
o
L
,
 
q
u
a
l
i
t
y
 
o
f
 
l
i
f
e
;
 
R
T
,
 
r
e
s
c
u
e
 
t
h
e
r
a
p
y
;
 
N
R
S
,
 
n
u
m
e
r
i
c
a
l
 
r
a
t
i
n
g
 
s
c
a
l
e
;
 
S
Q
,
 
s
l
e
e
p
 
q
u
a
l
i
t
y
;
 
T
D
S
,
 
t
r
a
n
s
d
e
r
m
a
l
 
d
e
l
i
v
e
r
y
 
s
y
s
t
e
m
;
 
v
R
S
,
 
v
e
r
b
a
l
 
r
a
t
i
n
g
 
s
c
a
l
e
;
 
v
A
S
,
 
v
i
s
u
a
l
 
a
n
a
l
o
g
u
e
 
s
c
a
l
e
.Therapeutics and Clinical Risk Management 2009:5 714
Deandrea et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
of 119 days, but 107 discontinued after the first 2 months, 
mainly because of death and insufficient pain relief. Among 
the cancer patients, 86.6% reported an ‘at least satisfactory’ 
pain relief throughout the study period. Eighty-four cancer 
patients reported adverse events; 31 events were probably 
drug-related and 26 were ADRs (the more frequent were 
nausea and vomiting).
Camba38 summarized 3 longitudinal multicentre studies 
conducted by the Sociedad Española del Dolor. The third 
study involved 164 cancer patients with moderate to severe 
pain, who did not respond to previous analgesics, and who 
were followed up for 8 weeks after the first administration 
of buprenorphine TDS. Fifteen percent of the patients started 
with 17.5 µg/hour and 82% started with 35 µg/hour of the 
drug. Mean pain intensity, measured with a visual analogue 
scale (VAS), at baseline was 7.4 and decreased to 3.2 at 
week 8 (P  0.001). This study also included a quality of life 
questionnaire and parameters such as physical fitness, social 
and daily activities, and how they felt significantly improved 
during the course of the observation period. Fifty-one patients 
discontinued the study; the results of adverse events were 
not reported for the cancer study alone.
Wirz45 conducted a controlled trial with the oral sustained-
release hydromorphone, transdermal fentanyl, and buprenor-
phine on randomly selected 174 cancer patients, to assess 
the difference in terms of gastrointestinal symptoms in 
long-term treatment (all patients were pretreated with their 
current opioid therapy for more than 28 days). Patients were 
selected for participation by random selection from a sample 
of outpatients undergoing pain therapy with one of the study 
medications. Apart from a significantly higher incidence of 
stool-free periods of 72 hour for transdermal opioids, there 
were no differences in the effects of the 3 drugs in terms of 
nausea, emesis, and constipation.
Apolone46 followed up 1801 advanced cancer patients 
with persistent pain of any degree, using several outcomes 
and endpoints, including pain intensity measured with a NRS, 
satisfaction, and quality of life: among the patients recruited, 
257 were consuming buprenorphine at baseline, with a mean 
TDS dose of 43.2 µg/hour (median 35) and an average 
increase to 50.0 at day 28. All the outcome measures consis-
tently improved over time, in terms of statistical significance 
and clinical relevance. For example, the worst pain differ-
ences were −1.4 points (95% confidence interval −1.1/−1.8, 
P  0.0001). The effect-size estimates indicated that on 
average, the endpoints based on pain intensity were more 
responsive (range 0.2 to 0.6) than those measuring pain 
relief, satisfaction, or quality of life (range 0.2 to 0.3), and 
the best measure was worst pain difference. About 34% of 
the patients had an improvement of at least 2 points in worst 
pain, nearly 48% improved less or were stable, 15% had 
a 20% improvement in pain relief, and 40% reported an 
increase in satisfaction. The most frequent side effects were 
constipation (56%) and sedation (51%), but the frequency 
of the symptoms rated by patients as ‘a lot/very much’ was 
always less than 25%.
estimate of the overall treatment  
effect on pain
When studies were evaluated according to the type of out-
comes and endpoints used to find a measure to pool studies 
and estimate the overall treatment effect, a substantial het-
erogeneity emerged that did not allow statistical pooling.
In the 6 RCTs, 3 studies28,31,44 shared the same primary 
outcome (the responder status), an endpoint that may be 
considered valid and relevant in this setting, but it was 
actually operationally defined in different ways (mentioned 
previously). The other primary outcomes were rescue 
therapy,32 patient satisfaction,40 and pain intensity.42 When 
we expanded this assessment to the secondary outcomes, 
among the wide list of measures used (from indicators of pain 
intensity to safety and quality of life), the only one used in 
all 6 RCTs was pain intensity, which became our candidate 
for a formal attempt for a statistical combination.
In the 6 observational studies, the same evaluation again 
yielded a very heterogeneous result: in 3 cases the primary 
endpoint was pain relief,33,34,36 in 2 it was pain intensity,38,46 
and in 1 it was safety.45
As 8 studies, 6 clinical trials28,31,32,40,42,44 and 2 observa-
tional studies,38,46 have used patients’ reported pain intensity, 
we focused on this subsample. Table 3 presents the details of 
the studies that were candidates for a pooling analysis.
A deeper analysis of the studies’ characteristics and 
efficacy estimates reported in the papers showed that in 
this subsample also, the type of data was not appropriate 
for combining the results. For example, although all the 
studies used some standardized measures of pain intensity, 
the assessment tools were different: in 4 cases NRS was 
used,40,42,44,46 in 3 cases VRS was used,28,31,35 and in 1 case 
VAS was used.38 In addition, for NRS different anchors were 
actually used to identify the least and worst pain intensity. 
In 4 cases28,31,32,40 it was not possible to distinguish the 
results between cancer and non-cancer patients. Finally, 
the period of time chosen by the authors to estimate the 
difference of pain intensity attributable to the intervention 
varied from 1028,32 to 56 days.38Therapeutics and Clinical Risk Management 2009:5 715
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estimate of overall safety and tolerability
After the narrative description of safety and tolerability given 
for each paper and study, we tried to summarize and integrate 
these important characteristics; however, papers describing 
the 12 clinical studies reported the safety and tolerability 
of the drugs under evaluation using different and heteroge-
neous methods and terms. Most authors reported side effects 
in terms of adverse events, ADR, or simply using a list of 
most frequent symptoms reported by patients. Sometimes, 
adverse events and ADR were also classified as severe. Some 
authors reported side effects that were attributable to opioid 
administration only, while others classified them according 
to the system or organ involved, such as skin, central nervous 
system, or according to the type, such as nausea, vomiting, 
and constipation. Given the large variability of the methods 
used, we tried to classify them into the following groups: 
adverse events, ADR, gastrointestinal (including nausea, 
vomiting, constipation), central nervous system (including 
confusion, dizziness), and skin (including pruritus and local 
erythema). Table 4 shows the results of such reclassifica-
tion and synthesis. Most of the times, it was not possible 
to identify the exact quantity and type of the side effects, 
as the authors did not report the estimates according to the 
type of patients (cancer vs non-cancer). In addition, the unit 
of analysis was not homogeneous across the studies (as the 
authors reported either the number of events or the number 
of patients with at least 1 event), yielding a quite unreliable 
classification of the phenomenon.
Discussion
Buprenorphine TDS has been available in most European 
countries since 2002, to treat moderate to severe chronic 
pain. The TDS formulation that allows for a slow release by 
minimizing the typical opioid side effects makes it a good 
alternative to the other oral opioids in clinical practice. The 
results from 3 clinical pivotal trials28,31,32 including only 
453 cancer patients, documented its analgesic efficacy, 
at least in terms of the responders’ status, and the safety 
profile that was typically opioid in nature and not differ-
ent from placebo in terms of incidence of reported events; 
local adverse events associated with TDS application were 
erythema and pruritus, while the most frequent systemic 
Table 3 Description of pain intensity outcomes and endpoints in 6 randomized clinical trials and 2 prospective observational studies 
investigating buprenorphine TDS effects in adult cancer patients
Reference Primary outcome Pain intensity 
measure
Details of the pain scale Mean pain at 
baseline for cancer 
patients (sd)
Mean pain after 
treatment (sd)
Assessment 
time (days)
Böhme28 Responder status 5-point (vRS) very severe, severe, 
moderate, slight, absent
not reported not reported 10
Sittl31 Responder status 5-point (vRS) very severe, severe, 
moderate, slight, absent
not reported not reported 15
Sorge32 Number of BP SL 
tablets required as 
rescue therapy
5-point (vRS) very severe, severe, 
moderate, slight, absent
not reported not reported 10
Likar40 Patient satisfaction 
with treatment
11-point (NRS) 
MPQ
No pain- worst pain 
imaginable 15 items then 
categorized 0 (no pain) to  
3 (worst pain imaginable)
not reported not reported 12
Pace42 Pain severity 11-point (NRS) 0 = no pain; 10 = maximum 
possible pain
6.4 (0.2) 3.9 (0.3) 56
SF-MPQ (vAS) 15 items for pain in the last 
week then categorized  
0 (no pain) to 3 (acute pain)
67.7 (2.1) 36.9 (1.2)
Poulain44 Responder status 11-point (NRS) No pain to pain as bad you 
can imagine
1.5 (1.5) 1.5 (1.5) 14
Camba38 Pain intensity vAS 0 cm = no pain to 
10 cm = maximum pain
7.4 (1.2) 3.2 (not reported) 56
Apolone46 worst and average 
pain intensity
11-point (NRS) No pain to pain as bad you 
can imagine worst, actual, 
least and average pain
6.4 (2.3) worst 
3.2 (2.6) actual
4.8 (2.5) worst 
2.3 (2.2) actual
28
Abbreviations: NRS, numerical rating scale;   vRS, verbal rating scale;   vAS, visual analog scale; SF-MPQ, Short-form McGill Pain Questionnaire.Therapeutics and Clinical Risk Management 2009:5 716
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adverse events were nausea and vomiting. Pharmacokinetics 
and pharmacodynamics data suggest that buprenorphine 
TDS may be safely used in aged patients and in renally 
impaired individuals, although the small sample size of the 
studies and the restriction in inclusion criteria did not allow 
any subgroup or interaction analysis. Post-marketing and 
outcome research of the prospective studies yielded satisfac-
tory results in terms of effectiveness, despite the presence of a 
large variability in inclusion/exclusion criteria and outcomes 
assessment. Safety and tolerability results were often reported 
together for both cancer and non-cancer patients, making it 
difficult to extract and summarize the findings across the 
individual original studies. Despite these limitations, the type 
of adverse events was in line with that expected, given the 
opioid nature of the drug, and the reported incidence from 
observational studies, when evaluable, was low, mostly in 
terms of serious events.
The evidence for comparative efficacy and safety is 
indeed scanty, as most of the efficacy data are from placebo 
trials. Only one RCT42 was designed to compare it with 
morphine. This trial had an open-label design and a very 
small sample size. As pointed out by other researchers,9 
well-designed and statistically powered controlled clinical 
trials focusing exclusively on treating cancer patients suf-
fering from pain using buprenorphine TDS are still lacking. 
In addition, our analysis based on a systematic review that 
included published papers up to April 2009 confirmed that 
the quality of the 19 reports describing 16 studies was poor 
and did not allow for safe data pooling. Studies, although 
stratified according to the study design, were very heteroge-
neous in terms of population included, interventions studied, 
comparators evaluated, and outcomes assessed. Even when 
the same outcome was formally assessed (eg, the responders’ 
status or the patients’ reported pain intensity), the differences 
in terms of operational definition of endpoints, timing of the 
assessment, or simply the type of measures used (NRS vs 
VRS vs VAS), made it impossible to identify a subsample 
for formal data synthesis and statistical pooling.
The results of this systematic review confirm the potential 
of this drug when delivered through a TDS, but it may be 
considered as a lost opportunity for a meta-analysis. The stud-
ies that we retrieved were very few, very heterogeneous, and 
reported results in a way that prevented an appropriate data 
extraction and data pooling. This fact might explain why TDS 
buprenorphine has not yet been recommended by national and 
international guidelines, and sometimes is not included in the 
list of reimbursable drugs at national or local levels.
In fact, the poor quality of pain studies is a well-
known phenomenon throughout the field, across the type 
of interventions, countries, and clinical settings. A recent 
literature review carried out by the European Palliative 
Care Research Collaborative Group to assess the quality of 
pain assessment in palliative care documented that in the 
230 papers retrieved and evaluated, the methods and tools 
Table 4 Local and systemic safety and tolerability adverse events and adverse drug reactions from 12 selected studies
Name of the first 
author
Number of patients 
with cancer
Number of AEs Number of ADRs % of patients reporting side 
effects or AEs related to
GI CNS Skin
Böhme28 83 NA NA NA NA NA
Sittl31 21 NA 6 NA NA NA
Sorge32 45 NA NA NA NA NA
Likar40 9 NA 0 NA NA NA
Pace42 52 15/26 TDS buprenorphine 0 19.2 38.4 NA
37/26 oral morphine 73.0 69.2
Poulain44 89 NA 2 18.0 4.8 NA
15.8 0.0
Griessinger33 3690 NA 18 NA NA NA
Muriel34 207 NA NA NA NA NA
Likar36 134 84 26 14.1 5.9 8.9
Camba38 164 NA NA NA NA NA
wirz45 174 NA NA NA NA NA
Apolone46,a 257 NA 25% 33.5 25.4 2.5
ain this study side effects were reported as ‘opioids related symptoms’ rated by patients as ‘a lot/very much’ impact.
Abbreviations: Ae, adverse event; ADR, adverse drug reaction; Gi, gastrointestinal; CNS, central nervous system; NA, not available; TDS, transdermal delivery system.Therapeutics and Clinical Risk Management 2009:5 717
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used were very heterogeneous and did not meet the criteria 
identified by experts as minimal standards.47,48
In conclusion, buprenorphine TDS has been observed 
to have good intrinsic (pharmacological) characteristics and 
promising clinical results, suggesting the need to appropriately 
review the evidence base for its utility. The results from this 
systematic literature review are not conclusive and suggest 
the need for 3 sequential initiatives: 1) a meta-analysis carried 
out on individual data to minimize the problems that we have 
found working on aggregated data; 2) an international initiative 
to find a consensus on definitions, methods, and measures of 
pain assessment in clinical research; and 3) a well-designed, 
large, multicenter, international comparative study to produce 
final evidence about the relative effectiveness and safety of the 
available third-level WHO opioids. These above-mentioned 
actions are are now being planned.
For the Cochrane Collaboration, one group has pub-
lished a protocol titled ‘Buprenorphine for cancer pain’. The 
authors planned to carry out a systematic review based on an 
electronic search of 5 databases, including the contact of the 
original authors of the primary studies for clarification, or to 
obtain missing information or individual data.49
A joint initiative of 3 non-profit organizations (Center for 
the Research and Evaluation of Pain, Norwegian University 
of Science and Technology, Italian National Cancer Institute) 
planned an expert panel meeting on the issues related to 
cancer-pain assessment in clinical research. The first meet-
ing involving experts from the USA and Europe, including 
representatives of FDA and EMEA, will be held in Milan, 
Italy, in September 2009.
Finally, on the basis of the results of this review and 
according to the preliminary results of a prospective outcome 
research study carried out in Italy on 1800 cancer patients 
with pain,50 a multicenter RCT to compare the efficacy of 
4 strong opioids on cancer pain (buprenorphine, morphine, 
fentanyl, and oxycodone) will be launched at the end of this 
year, involving about 80 centers and 1000 patients.
Disclosures
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